Patents Assigned to ONCOLÓGICA DE VALL HEBRON
-
Patent number: 11858972Abstract: The present invention relates to new peptidic compounds, more specifically to micropeptides derived from lncRNAs implicated in cancer and cellular plasticity. It also relates to the use of the said micropeptides in the treatment of proliferative diseases, more specifically in the treatment of cancer.Type: GrantFiled: March 15, 2019Date of Patent: January 2, 2024Assignee: Fundació Privada Institut d'Investigació Oncològica de Vall HebronInventors: Maria Abad Méndez, Olga Boix Sánchez, Emanuela Greco, Iñaki Merino Valverde
-
Patent number: 11427621Abstract: The invention relates to a polypeptide comprising or consisting of the polypeptide of SEQ ID NO: 1 wherein the residue X at position 89 of SEQ ID NO: 1 is not a cysteine, or a functionally equivalent variant of said polypeptide wherein the residue X at position 89 of SEQ ID NO: 1 is not a cysteine and their use in medicine, particularly in the prevention and/or treatment of cancer.Type: GrantFiled: July 17, 2017Date of Patent: August 30, 2022Assignees: INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS, FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL HEBRONInventors: Laura Soucek, Toni Jauset González, Marie-Eve Beaulieu
-
Patent number: 11339205Abstract: The invention relates to a Myc dominant negative mutant, called Omomyc, for use in medicine and for use in the prevention and/or treatment of cancer. The invention also refers to a fusion protein comprising Omomyc and pharmaceutical composition thereof and their use in medicine and, in particular, for treatment of cancer.Type: GrantFiled: June 6, 2019Date of Patent: May 24, 2022Assignees: FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ, ONCOLÓGICA DE VALL HEBRONInventors: Laura Soucek, Marie-Eve Beaulieu
-
Patent number: 10583191Abstract: Described herein are antibodies that target Leukemia Inhibitory Factor (LIF). Also described herein are uses of these antibodies for the treatment of cancer.Type: GrantFiled: December 18, 2017Date of Patent: March 10, 2020Assignees: MOSAIC BIOMEDICALS SLU, FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÓGICA DE VALL HEBRON, FUNDACIÓ PRIVADA INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATSInventors: Joan Seoane Suarez, Judit Anido Folgueira
-
Patent number: 10370434Abstract: The invention relates to a Myc dominant negative mutant, called Omomyc, for use in medicine and for use in the prevention and/or treatment of cancer. The invention also refers to a fusion protein comprising Omomyc and pharmaceutical composition thereof and their use in medicine and, in particular, for treatment of cancer.Type: GrantFiled: May 7, 2014Date of Patent: August 6, 2019Assignee: FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA DE VALL HEBRONInventors: Laura Soucek, Marie-Eve Beaulieu
-
Patent number: 10206999Abstract: Described herein are antibodies that target Leukemia Inhibitory Factor (LIF). Also described herein are uses of these antibodies for the treatment of cancer.Type: GrantFiled: January 26, 2018Date of Patent: February 19, 2019Assignees: Mosaic Biomedicals, S.L., Fundació Privada Institut d'Investigació Oncológica de Vall Hebron, Fundació Privada Institució Catalana de Recerca | Estudis AvançatsInventors: Joan Seoane Suarez, Judit Anido Folgueira
-
Publication number: 20160122415Abstract: The invention relates to a Myc dominant negative mutant, called Omomyc, for use in medicine and for use in the prevention and/or treatment of cancer. The invention also refers to a fusion protein comprising Omomyc and pharmaceutical composition thereof and their use in medicine and, in particular, for treatment of cancer.Type: ApplicationFiled: May 7, 2014Publication date: May 5, 2016Applicant: FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA DE VALL HEBRON (FPIIOVH)Inventors: Laura SOUCEK, Marie-Eve BEAULIEU
-
Patent number: 8389227Abstract: The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor. The invention provides antibodies or fragments thereof that recognizes an epitope of a HER2 receptor truncated form, said epitope being defined by a sequence included in SEQ ID NO: 2. The invention also provides a method of cancer diagnosis, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ ID NO: 1 in a patient sample.Type: GrantFiled: June 5, 2009Date of Patent: March 5, 2013Assignees: Fundacio Privada Institut de Recerca Hospital Universitari Vall Hebron, Fundacio Privada Institucio Catalana de Recera I Estudis Avancats, Fundacio Privada Institut d'Investigacio Oncologica de Vall HebronInventors: Joaquin Arribas Lopez, Kim Pedersen, Pier-Davide Angellini, Josep Liuis Parra Palau, Sirle Laos, Jose Baselga Torres
-
Publication number: 20090311262Abstract: The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor. The invention provides antibodies or fragments thereof that recognises an epitope of a HER2 receptor truncated form, said epitope being defined by a sequence included in SEQ ID NO: 2. The invention also provides a method of cancer diagnosis, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ ID NO: 1 in a patient sample.Type: ApplicationFiled: June 5, 2009Publication date: December 17, 2009Applicants: Fundacio Privada Institut de Recerca Hospital Universitari Vall Hebron, Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats, Fundacio Privada Institut d'Investigacio Oncologica de Vall HebronInventors: Joaquin Arribas Lopez, Kim Pedersen, Pier-Davide Angellini, Josep Liuis Parra Palau, Sirle Laos, Jose Baselga Torres